Jul. 29 at 2:24 PM
Pipeline Update from Quoin Pharmaceuticals (Nasdaq:
$QNRX)
@QuoinPharma is advancing QRX003 toward potential commercialization as the first approved treatment for Netherton Syndrome. Two pivotal clinical trials remain on track, with an NDA submission anticipated in the second half of 2026. The company has active studies across the U.S., Europe, and the Middle East. Positive early data supports expansion into Peeling Skin Syndrome, and the topical rapamycin program is advancing toward clinical trials in 2026. Quoin is entering pre-commercialization mode while continuing to grow its rare disease pipeline.
https://prismmarketview.com/quoin-advances-qrx003-toward-commercialization-in-netherton-syndrome-and-expands-rare-disease-pipeline/
